Drug Profile
Research programme: tuberculosis therapeutics - AstraZeneca/Global Alliance for TB Drug Development
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator AstraZeneca; Global Alliance for TB Drug Development
- Class Antituberculars
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis